Literature DB >> 2024388

Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer.

G Gerber1, G W Chodak.   

Abstract

The value of routine bone scans as a staging procedure was assessed in patients with newly diagnosed prostate cancer. Records from 277 patients were reviewed retrospectively to determine the serum acid and alkaline phosphatases, the presence or absence of bone pain, and the results of bone scans and other radiographic studies at the time of initial diagnosis. We determined the sensitivity and specificity of an abnormal acid phosphatase, an abnormal alkaline phosphatase, and the presence of bone pain used in combination for assessing bone metastases. If at least one of these three parameters was present, the sensitivity was 97 percent, whereas if all three tests were normal, the specificity was 78 percent. The negative predictive value for all three tests combined is 99 percent. These results suggest that a routine bone scan to stage patients with newly diagnosed prostate cancer who have no bone pain and normal acid and alkaline phosphatases may not be warranted in all cases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2024388     DOI: 10.1016/0090-4295(91)80101-c

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

1.  [Radionuclide bone scan in patients with newly diagnosed prostate cancer. Clinical aspects and cost analysis].

Authors:  T Klatte; D Klatte; M Böhm; E P Allhoff
Journal:  Urologe A       Date:  2006-10       Impact factor: 0.639

Review 2.  Optimal cost-effective staging evaluations in prostate cancer.

Authors:  Gregory L Lacy; Douglas W Soderdahl; Javier Hernandez
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

3.  Scintigraphic changes in bone metastasis from prostate cancer after hormonal therapy--comparison with tumor markers and bone X-ray.

Authors:  K Koizumi; G Uchiyama; H Komatsu
Journal:  Ann Nucl Med       Date:  1994-11       Impact factor: 2.668

4.  Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?

Authors:  Seung Hwan Lee; Mun Su Chung; Kyung Kgi Park; Chan Dong Yom; Dae Hoon Lee; Byung Ha Chung
Journal:  World J Urol       Date:  2011-07-16       Impact factor: 4.226

5.  A narrowing range of bone scan in newly diagnosed prostate cancer patients: A retrospective comparative study.

Authors:  Berat Cem Özgür; Sinan Gültekin; Musa Ekici; Demet Yılmazer; Murat Alper
Journal:  Urol Ann       Date:  2015 Apr-Jun

Review 6.  Shining Damaged Hearts: Immunotherapy-Related Cardiotoxicity in the Spotlight of Nuclear Cardiology.

Authors:  David Kersting; Stephan Settelmeier; Ilektra-Antonia Mavroeidi; Ken Herrmann; Robert Seifert; Christoph Rischpler
Journal:  Int J Mol Sci       Date:  2022-03-30       Impact factor: 5.923

Review 7.  Imaging in genitourinary cancer from the urologists' perspective.

Authors:  P Tsakiris; J de la Rosette
Journal:  Cancer Imaging       Date:  2007-05-28       Impact factor: 3.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.